Recent Updates
Recently added Catalysts
KAPA Positive Sentiment

Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Wednesday, September 9, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Kairos Pharma, a clinical-stage biopharmaceutical company, will present at the H.C. Wainwright 28th Annual Global Investment Conference. CEO John Yu will provide a corporate overview on September 14, 2026, at the Lotte New York Palace Hotel. This event aims to showcase the company's efforts in addressing cancer drug resistance.

Market Sentiment Analysis

POSITIVE FACTORS

  • Kairos Pharma is actively engaging with investors.
  • The presentation highlights the company's focus on cancer drug resistance.
  • Participation in a prominent investment conference enhances visibility.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~7 mo
Medium dilution risk
Lead asset
Apalutamide
Phase 2 · Castration-resistant Prostate Cancer

Full Press Release Details

LOS ANGELES--(BUSINESS WIRE)---- $KAPA #HCW--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announces that John Yu, MD, CEO and Chairman, will present in person a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference. The conference is being held on September 14 – 16, 2026 at the Lotte New York Palace Hotel. Presentation Date: September 14, 2026 Time: 4:00 PM Eastern Time (Holmes 1) Webcast Link:

Frequently Asked Questions

When will Kairos Pharma present at the conference?

Kairos Pharma will present on September 14, 2026.

Who will present for Kairos Pharma?

John Yu, MD, CEO and Chairman, will present.

Where is the H.C. Wainwright Conference held?

The conference is at the Lotte New York Palace Hotel.

What is the focus of Kairos Pharma?

The company focuses on overcoming cancer drug resistance.

ShareAdd on Google
Tags: KAPA Viatris Investor Conferences Healthcare H.C. Wainwright investment conference cancer drug resistance clinical-stage biopharmaceutical
Last updated: Sep 9, 2026

Biotech snapshot

Cash runway
$3M liquidity · $0M/mo burn
~7 mo
Medium dilution risk
Lead asset
ApalutamidePhase 2
Castration-resistant Prostate Cancer →